

Appl. No. : 09/918,026
Filed : July 30, 2001

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

LISTING OF CLAIMS

1. (Currently Amended) An antisense oligonucleotide ~~8 to 50~~ 12 to 30 nucleobases in length targeted to the coding region of a nucleic acid molecule encoding human acyl CoA cholesterol acyltransferase-2 (SEQ ID NO: 3), wherein said antisense oligonucleotide specifically hybridizes with said region and inhibits the expression of a nucleic acid molecule encoding acyl CoA cholesterol acyltransferase-2 by at least ~~60%~~ 55%.
2. (Canceled)
3. (Canceled)
4. (Previously Presented) The antisense oligonucleotide of claim 1 which comprises at least one modified internucleoside linkage.
5. (Previously Presented) The antisense oligonucleotide of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.
6. (Previously Presented) The antisense oligonucleotide of claim 1 which comprises at least one modified sugar moiety.
7. (Previously Presented) The antisense oligonucleotide of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
8. (Previously Presented) The antisense oligonucleotide of claim 1 which comprises at least one modified nucleobase.
9. (Previously Presented) The antisense oligonucleotide of claim 8 wherein the modified nucleobase is a 5-methylcytosine.
10. (Previously Presented) The antisense oligonucleotide of claim 1 which is a chimeric oligonucleotide.
11. (Canceled)
12. (Previously Presented) A composition comprising the antisense oligonucleotide of claim 1 and a pharmaceutically acceptable carrier or diluent.
13. (Original) The composition of claim 12 further comprising a

Appl. No. : **09/918,026**
Filed : **July 30, 2001**

colloidal dispersion system.

14-20. (Canceled)

Appl. No. : **09/918,026**
Filed : **July 30, 2001**

SUMMARY OF INTERVIEW

Identification of Claims Discussed

All of the pending claims were discussed.

Principal Arguments and Other Matters

Applicant's representatives discussed the pending Office Action and the issues raised by the Examiner with regard to the 103(a) and written description rejections.

Results of Interview

It was agreed that if Applicant provides a reference that discusses reasons for not targeting ACAT-1 (e.g. toxicity reasons), the 103 are rejection of record would be overcome. Furthermore, it was agreed that deleting "60%" from claim 1 and adding a range of nucleotides would overcome the written description rejection.